| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2025 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 2,526 | $14.54 | $36,728.04 | -0.9% | +61.9% | - | |
| Jul 19, 2025 | HYEX Healthy Extracts Inc. | Swanson Donald William | President | Buy | 13,075,920 | $0.00 | - | New | - | - | |
| Jul 18, 2025 | TSNDF Terrascend Corp. | Stauffer Keith | CFO | Sell | 52,500 | $0.39 | $20,265.00 | -3.1% | - | - | |
| Jul 17, 2025 | JNJ Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3,129,829.56 | -64.2% | +17.3% | - | |
| Jul 17, 2025 | ESPR Esperion Therapeutics, Inc. | Looker Benjamin56 | General Counsel | Sell | 1,304 | $1.13 | $1,469.61 | -0.3% | +103.2% | - | |
| Jul 17, 2025 | ESPR Esperion Therapeutics, Inc. | Halladay Benjamin | Chief Financial Officer | Sell | 11 | $1.12 | $12.27 | - | +103.2% | - | |
| Jul 16, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 50,326 | $50.27 | $2,530,034.04 | -8.8% | +4.2% | - | |
| Jul 14, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 18,900 | $28.72 | $542,808.00 | -27.8% | +28.6% | - | |
| Jul 14, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,572 | $47.82 | $122,993.04 | -1.6% | +5.2% | - | |
| Jul 14, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $47.70 | $552,418.33 | -17.6% | +5.2% | - | |
| Jul 14, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $64.88 | $25,952.00 | -0.5% | +35.9% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | Sell | 2,673 | $14.28 | $38,170.44 | -1.8% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Boyle Dana | Chief Accounting Officer | Sell | 1,193 | $14.28 | $17,036.04 | -0.6% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Jeffs Roger66 | Chief Executive Officer | Sell | 20,252 | $14.28 | $289,198.56 | -1.9% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 2,576 | $14.28 | $36,785.28 | -1.3% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 4,797 | $14.28 | $68,501.16 | -2.1% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 11,580 | $14.28 | $165,362.40 | -2.8% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 5,327 | $14.28 | $76,069.56 | -1.9% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Jeffs Roger66 | Chief Executive Officer | Sell | 20,252 | $14.28 | $289,198.56 | -1.9% | +64.2% | - | |
| Jul 14, 2025 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 7,836 | $14.28 | $111,898.08 | -1.3% | +64.2% | - | |
| Jul 10, 2025 | ELTP Elite Pharmaceuticals Inc /nv/ | Kirkov Kirko | Chief Commercial Officer | Buy | 16,366 | $0.59 | $9,639.57 | New | - | - | |
| Jul 10, 2025 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 457 | $135.00 | $61,695.00 | -8.8% | +3.1% | - | |
| Jul 10, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $300.31 | $3,303,393.71 | -6.1% | +49.6% | - | |
| Jul 9, 2025 | NBIX Neurocrine Biosciences Inc | Onyia Jude54 | Chief Scientific Officer | Sell | 59,819 | $130.46 | $7,803,687.65 | -76.6% | +2.6% | - | |
| Jul 9, 2025 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 33,044 | $0.18 | $5,938.01 | +0.5% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.